Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Biogen
The study was an open-label, multi-center, international post-marketing study (phase 4). Eligible patients were interferon naïve patients suffering from relapsing MS. The duration of a subject's participation in the study was up to a maximum 26 months.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Relapsing Remitting Multiple Sclerosis
Interferon naïve
Eligible for interferon beta-1a (AVONEX®) therapy as per Summary of Product Characteristics:
Subject has had relapsing MS for \> 1 year
Subject has had experienced 2 exacerbations in the last 2 years
Subject had an EDSS \[5\] score of \< 5.5
Subject was ambulant
You may not be if
Diagnosis of MS defined as progressive
History of any significant cardiac, hepatic, pulmonary, or renal disease; immune deficiency; or other medical conditions that would preclude therapy with interferon beta
History of severe allergic or anaphylactic reactions or history of hypersensitivity to human albumin
History of seizures within the 3 months prior to starting this study
History of intolerance to acetaminophen (paracetamol), ibuprofen, naproxen or other NSAIDs, that would preclude use of at least one of these during the study
History of intolerance to interferons
Previous use of interferon beta
Female subjects who were pregnant or breast-feeding
For female subjects, unless postmenopausal or surgically sterile, unwillingness to practice effective contraception
Clareo Health | Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a?
